Vise Technologies Inc. Makes New $8.49 Million Investment in Abbott Laboratories $ABT

Vise Technologies Inc. purchased a new stake in shares of Abbott Laboratories (NYSE:ABT) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 85,874 shares of the healthcare product maker’s stock, valued at approximately $8,487,000.

A number of other hedge funds have also modified their holdings of ABT. Elwood & Goetz Wealth Advisory Group LLC boosted its position in Abbott Laboratories by 3.1% during the third quarter. Elwood & Goetz Wealth Advisory Group LLC now owns 3,216 shares of the healthcare product maker’s stock valued at $318,000 after purchasing an additional 97 shares during the last quarter. Parkway Wealth Management Group LLC grew its stake in Abbott Laboratories by 3.2% in the third quarter. Parkway Wealth Management Group LLC now owns 3,208 shares of the healthcare product maker’s stock valued at $317,000 after purchasing an additional 98 shares in the last quarter. St. Johns Investment Management Company LLC increased its position in Abbott Laboratories by 1.0% in the 2nd quarter. St. Johns Investment Management Company LLC now owns 9,859 shares of the healthcare product maker’s stock worth $895,000 after purchasing an additional 101 shares during the last quarter. AA Financial Advisors LLC increased its position in Abbott Laboratories by 1.7% in the 3rd quarter. AA Financial Advisors LLC now owns 6,186 shares of the healthcare product maker’s stock worth $611,000 after purchasing an additional 101 shares during the last quarter. Finally, Eagle Bay Advisors LLC increased its position in Abbott Laboratories by 1.2% in the 3rd quarter. Eagle Bay Advisors LLC now owns 8,448 shares of the healthcare product maker’s stock worth $835,000 after purchasing an additional 102 shares during the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Wall Street Zen upgraded Abbott Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, October 24th. Citigroup lowered their price target on Abbott Laboratories from $125.00 to $122.00 and set a “buy” rating for the company in a research note on Thursday, October 22nd. Rothschild & Co Redburn upgraded Abbott Laboratories from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $119.00 to $127.00 in a report on Friday, October 2nd. TD Cowen cut their price objective on shares of Abbott Laboratories from $135.00 to $118.00 and set a “buy” rating on the stock in a research report on Thursday, October 22nd. Finally, JPMorgan Chase & Co. reduced their target price on shares of Abbott Laboratories from $120.00 to $118.00 and set an “overweight” rating for the company in a research note on Thursday, October 22nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average price target of $118.32.

Abbott Laboratories Trading Up 0.1%

Abbott Laboratories stock opened at $106.33 on Monday. Abbott Laboratories has a one year low of $81.97 and a one year high of $132.02. The company’s fifty day moving average price is $104.36 and its two-hundred day moving average price is $102.06. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The company has a market capitalization of $183.99 billion, a price-to-earnings ratio of 39.68, a PEG ratio of 1.86 and a beta of 0.54.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.42. The company had revenue of $13.01 billion during the quarter, compared to analysts’ expectations of $12.99 billion. Abbott Laboratories had a return on equity of 17.97% and a net margin of 9.75%. The business’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.30 earnings per share. On average, analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 94.03%.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott began the pivotal CROWN-MV trial for its investigational Cephea Mitral Valve System, designed as a minimally invasive treatment for symptomatic mitral valve disease patients who are ineligible for surgery or transcatheter repair. Successful development could expand Abbott’s structural-heart portfolio, although the device remains investigational and carries clinical and regulatory risk. Abbott initiates pivotal trial for Cephea device
• Positive Sentiment: Industry reports forecast strong expansion in point-of-care diagnostics across South and Central America and continued growth in home INR monitoring. Abbott is listed among the key suppliers, suggesting potential long-term opportunities for its diagnostics business through testing volume, instruments and recurring consumables. South and Central America point-of-care diagnostics market Point-of-care INR testing market
• Neutral Sentiment: Discussion of Abbott’s approaching breakup highlights the potential for value creation through separating businesses, but also raises questions about execution, valuation and how costs and growth prospects will be allocated among the resulting companies. Can Abbott Laboratories Stay Reasonable As Its Breakup Nears?
• Negative Sentiment: Dexcom exceeded expectations and raised guidance, underscoring robust demand for continuous glucose-monitoring wearables but also intensifying competitive pressure on Abbott’s FreeStyle Libre franchise. Stronger execution by Dexcom could weigh on expectations for Abbott’s diabetes-care growth. Dexcom shakes off Abbott-tied malaise
• Negative Sentiment: Argus downgraded Abbott Laboratories, adding a near-term valuation and analyst-sentiment headwind. Abbott Laboratories stock gets downgrade from Argus

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.